Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)
Standard
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). / Vermehren, Johannes; Serfert, Yvonne; Cornberg, Markus; Stoehr, Albrecht; Klinker, Hartwig; Simon, Karl-Georg; Teuber, Gerlinde; Deterding, Katja; Schulze Zur Wiesch, Julian; Jung, Maria-Christina; Manns, Michael P; Zeuzem, Stefan; Wedemeyer, Heiner; Sarrazin, Christoph.
In: Z GASTROENTEROL, Vol. 58, No. 9, 09.2020, p. 841-846.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)
AU - Vermehren, Johannes
AU - Serfert, Yvonne
AU - Cornberg, Markus
AU - Stoehr, Albrecht
AU - Klinker, Hartwig
AU - Simon, Karl-Georg
AU - Teuber, Gerlinde
AU - Deterding, Katja
AU - Schulze Zur Wiesch, Julian
AU - Jung, Maria-Christina
AU - Manns, Michael P
AU - Zeuzem, Stefan
AU - Wedemeyer, Heiner
AU - Sarrazin, Christoph
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2020/9
Y1 - 2020/9
N2 - Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.
AB - Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.
KW - Antiviral Agents/therapeutic use
KW - Carbamates/therapeutic use
KW - Drug Therapy, Combination
KW - Genotype
KW - Hepacivirus/drug effects
KW - Hepatitis C, Chronic/drug therapy
KW - Heterocyclic Compounds, 4 or More Rings/therapeutic use
KW - Humans
KW - Macrocyclic Compounds/therapeutic use
KW - Registries
KW - Sofosbuvir/therapeutic use
KW - Sulfonamides/therapeutic use
KW - Sustained Virologic Response
KW - Treatment Outcome
U2 - 10.1055/a-1217-7669
DO - 10.1055/a-1217-7669
M3 - SCORING: Journal article
C2 - 32947629
VL - 58
SP - 841
EP - 846
JO - Z GASTROENTEROL
JF - Z GASTROENTEROL
SN - 0044-2771
IS - 9
ER -